Proteomics International Laboratories Ltd
ASX:PIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its Country Average (5.8), the stock would be worth AU$0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | AU$0.25 |
0%
|
| Country Average | 5.8 | AU$0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
38.5m AUD | 0 | -4.2 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 599.5 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 11.6 | 26 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 9.5 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 32.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 13.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 10.1 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 9.2 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 16.4 | 47.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 7.1 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 11.7 | 29.9 |
Market Distribution
Other Multiples
Proteomics International Laboratories Ltd
Glance View
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
